Musculoskeletal (Rheum/Ortho) drugs

64 results

  • actemra

    (tocilizumab)
    Genentech, Inc.
    ACTEMRA (tocilizumab) is indicated for treating moderately to severely active rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis, severe cytokine release syndrome from CAR T-cell therapy, and COVID-19 in hospitalized adults requiring respiratory support.

  • acthar

    (Repository Corticotropin)
    Mallinckrodt ARD LLC
    Acthar Gel is indicated for treating infantile spasms in infants under 2, acute exacerbations of multiple sclerosis in adults, and as adjunctive therapy for various rheumatic disorders. It is also used for certain collagen diseases, severe dermatologic and allergic conditions, ophthalmic inflammatory diseases, symptomatic sarcoidosis, and nephrotic syndrome.

  • amjevita

    (adalimumab-atto)
    Amgen Inc
    AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.

  • apadaz

    (Benzhydrocodone and Acetaminophen)
    KVK-Tech, Inc.
    APADAZ is indicated for the short-term management of acute pain requiring an opioid analgesic when alternative treatments are inadequate. It should be used cautiously due to the risks of addiction, abuse, and misuse. The treatment duration is limited to no more than 14 days.

  • arcalyst

    (rilonacept)
    Kiniksa Pharmaceuticals (UK), Ltd.
    ARCALYST (rilonacept) is indicated for treating Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, as well as for maintaining remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) and treating recurrent pericarditis in patients aged 12 and older.

  • belbuca

    (buprenorphine hydrochloride)
    BioDelivery Sciences International Inc
    BELBUCA is indicated for managing severe and persistent pain requiring long-term opioid treatment when other options are inadequate. It is not intended for as-needed use and should be reserved for patients unable to tolerate or achieve relief with non-opioid or immediate-release opioids due to risks of addiction and overdose.

  • benlysta

    (belimumab)
    GlaxoSmithKline LLC
    BENLYSTA (belimumab) is indicated for patients aged 5 and older with active systemic lupus erythematosus and active lupus nephritis, both receiving standard therapy. Its efficacy in severe active central nervous system lupus is not evaluated, hence it is not recommended for such cases.

  • bimzelx

    (bimekizumab)
    UCB, Inc.
    BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis with inflammation, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in adults who qualify for systemic therapy or phototherapy.

  • butrans

    (buprenorphine)
    Purdue Pharma LP
    BUTRANS is indicated for managing severe and persistent pain requiring long-term opioid treatment when other options are insufficient. It is not for as-needed use and is reserved for patients who cannot tolerate or have inadequate relief from alternative treatments due to the risks of addiction and overdose.

  • celebrex

    (Celecoxib)
    PFIZER LABORATORIES DIV PFIZER INC
    CELEBREX is indicated for managing signs and symptoms of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis (in patients aged 2 and older), ankylosing spondylitis, acute pain in adults, and primary dysmenorrhea.